GSK Gsk Plc

By Rory Gallivan

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that it has submitted an application to the European Medicines Agency to widen the uses for which its pulmonary arterial hypertension treatment Ambrisentan can be marketed.

Glaxo said its application seeks "to extend the current therapeutic indication to include its use in initial combination therapy for patients with pulmonary arterial hypertension."

The application is based on the results of a study conducted with biotechnology company Gilead Sciences Inc (GILD), Glaxo said.

At 1205 GMT, Glaxo shares were down 4 pence, or 0.3%, at 1,382 pence, valuing the company at 67.2 billion pounds ($105.4 million).

Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires